CorVista wins FDA clearance for AI heart failure assessment add-on

The US Food and Drug Administration (FDA) has granted clearance for an AI-powered, non-invasive test by CorVista Health. The new add-on helps identify elevated pulmonary capillary wedge pressure (PCWP), a key indicator of heart failure, replacing the need for invasive catheter procedures in certain patient groups.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.